| Joshua A Morris, PHD | |
|
16770 Sw Edy Rd Ste 102, Sherwood, OR 97140-9679 | |
| (503) 216-9600 | |
| Not Available |
| Full Name | Joshua A Morris |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 5 Years |
| Location | 16770 Sw Edy Rd Ste 102, Sherwood, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093327140 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 11453705-2501 (Utah) | Secondary |
| 103TC0700X | Psychologist - Clinical | 3429 (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
Age-related decline in the efficacy of DNA repair may underlie reproductive aging, say researchers.
Engineers are to develop new imaging technology that could provide more accurate cancer treatments.
PENTAX Medical Company, a healthcare industry leader in endoscopic imaging, announces the U.S. launch of the EPK-i®5010 Video Processor with PENTAX i-SCAN™, the industry's highest* resolution HD+ imaging technology for flexible endoscopy.
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.
› Verified 2 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
Age-related decline in the efficacy of DNA repair may underlie reproductive aging, say researchers.
Engineers are to develop new imaging technology that could provide more accurate cancer treatments.
PENTAX Medical Company, a healthcare industry leader in endoscopic imaging, announces the U.S. launch of the EPK-i®5010 Video Processor with PENTAX i-SCAN™, the industry's highest* resolution HD+ imaging technology for flexible endoscopy.
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua A Morris, PHD Po Box 3158, Portland, OR 97208-3158 Ph: (503) 215-6494 | Joshua A Morris, PHD 16770 Sw Edy Rd Ste 102, Sherwood, OR 97140-9679 Ph: (503) 216-9600 |
News Archive
Age-related decline in the efficacy of DNA repair may underlie reproductive aging, say researchers.
Engineers are to develop new imaging technology that could provide more accurate cancer treatments.
PENTAX Medical Company, a healthcare industry leader in endoscopic imaging, announces the U.S. launch of the EPK-i®5010 Video Processor with PENTAX i-SCAN™, the industry's highest* resolution HD+ imaging technology for flexible endoscopy.
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.
› Verified 2 days ago
Dr. Breanna Barr, PSY.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 22566 Sw Washington St Ste 201, Sherwood, OR 97140 Phone: 503-496-7470 | |
Bethany Michelle Zander, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 22344 Sw Main St, Sherwood, OR 97140 Phone: 219-793-2360 Fax: 503-625-3768 | |
Dr. Sherry Rose Beckmann, PSYCHOLOGIST, EDD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 22831 Sw Forest Creek Dr Ste B, Sherwood, OR 97140 Phone: 503-625-6559 Fax: 541-871-7851 | |
Amy M Schlapper, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 22344 Sw Main St, Sherwood, OR 97140 Phone: 503-625-2768 | |
Dr. Dean Ryan Longfellow, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 16850 Sw Gleneagle Dr, Suite 16b, Sherwood, OR 97140 Phone: 503-703-1222 | |
Jacqueline J Head, PSY.D. PC Psychologist Medicare: May Accept Medicare Assignments Practice Location: 22344 Sw Main St, Sherwood, OR 97140 Phone: 503-625-2768 Fax: 503-625-3768 |